FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Kelly John C.		 2. Issuer Name and Ticker or Trading Symbol

MEDICINES CO /DE [ MDCO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

8 SYLVAN WAY		 3. Date of Earliest Transaction (MM/DD/YYYY)

9/26/2019
(Street)

PARSIPPANY, NJ 07054
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/6/2020  D  32148 D (1)(2)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option $16 9/26/2019  G   V   25000 (3) 5/26/2014 4/26/2021 Common Stock 25000 $0 0 D  
Stock Option $16 9/26/2019  G   V 25000 (3)   5/26/2014 4/26/2021 Common Stock 25000 $0 25000 I By trust 
Stock Option $18.18 9/26/2019  G   V   13259 (3) 5/26/2012 5/26/2021 Common Stock 13259 $0 0 D  
Stock Option $18.18 9/26/2019  G   V 13259 (3)   5/26/2012 5/26/2021 Common Stock 13259 $0 13259 I By trust 
Stock Option $21.14 9/26/2019  G   V   12039 (3) 5/22/2013 5/22/2022 Common Stock 12039 $0 0 D  
Stock Option $21.14 9/26/2019  G   V 12039 (3)   5/22/2013 5/22/2022 Common Stock 12039 $0 12039 I By trust 
Stock Option $33.13 9/26/2019  G   V   9763 (3) 5/30/2014 5/30/2023 Common Stock 9763 $0 0 D  
Stock Option $33.13 9/26/2019  G   V 9763 (3)   5/30/2014 5/30/2023 Common Stock 9763 $0 9763 I By trust 
Stock Option $27.78 9/26/2019  G   V   10016 (3) 5/29/2015 5/29/2024 Common Stock 10016 $0 0 D  
Stock Option $27.78 9/26/2019  G   V 10016 (3)   5/29/2015 5/29/2024 Common Stock 10016 $0 10016 I By trust 
Stock Option $28.14 9/26/2019  G   V   16512 (3) 5/28/2016 5/28/2025 Common Stock 16512 $0 0 D  
Stock Option $28.14 9/26/2019  G   V 16512 (3)   5/28/2016 5/28/2025 Common Stock 16512 $0 16512 I By trust 
Stock Option $37.22 9/26/2019  G   V   9700 (3) 5/26/2017 5/26/2026 Common Stock 9700 $0 0 D  
Stock Option $37.22 9/26/2019  G   V 9700 (3)   5/26/2017 5/26/2026 Common Stock 9700 $0 9700 I By trust 
Stock Option $39.39 9/26/2019  G   V   8577 (3) 5/25/2018 5/25/2027 Common Stock 8577 $0 0 D  
Stock Option $39.39 9/26/2019  G   V 8577 (3)   5/25/2018 5/25/2027 Common Stock 8577 $0 8577 I By trust 
Stock Option $33.86 9/26/2019  G   V   9141 (3) 5/31/2019 5/31/2028 Common Stock 9141 $0 0 D  
Stock Option $33.86 9/26/2019  G   V 9141 (3)   5/31/2019 5/31/2028 Common Stock 9141 $0 9141 I By trust 
Stock Option $16.00 1/6/2020  D     25000   (4) (4)Common Stock 25000 $0 0 I By trust 
Stock Option $18.18 1/6/2020  D     13259   (4) (4)Common Stock 13269 $0 0 I By trust 
Stock Option $21.14 1/6/2020  D     12039   (4) (4)Common Stock 12039 $0 0 I By trust 
Stock Option $33.13 1/6/2020  D     9763   (4) (4)Common Stock 9763 $0 0 I By trust 
Stock Option $27.78 1/6/2020  D     10016   (4) (4)Common Stock 10016 $0 0 I By trust 
Stock Option $37.22 1/6/2020  D     9700   (4) (4)Common Stock 9700 $0 0 I By trust 
Stock Option $28.14 1/6/2020  D     16512   (4) (4)Common Stock 16512 $0 0 I By trust 
Stock Option $39.39 1/6/2020  D     8577   (4) (4)Common Stock 8577 $0 0 I By trust 
Stock Option $34.81 1/6/2020  D     8410   (4) (4)Common Stock 8410 $0 0 D  
Stock Option $33.86 1/6/2020  D     9141   (4) (4)Common Stock 9141 $0 0 I By trust 
Explanation of Responses:
(1) Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").
(2) The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
(3) On September 26, 2019, the Reporting Person gifted stock options to a family trust. The Reporting Person's adult children maintain investment control over the family trust.
(4) Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Kelly John C.
8 SYLVAN WAY
PARSIPPANY, NJ 07054		X
Signatures
/s/ Stephen M. Rodin, Attorney-in-Fact for John C. Kelly1/6/2020
**Signature of Reporting PersonDate
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Medicines Charts.
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Medicines Charts.